-
Mashup Score: 8Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy - 26 day(s) ago
Press to close the select your country window or navigate to it’s content. TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody’s Investor Services (“Moody’s”) has raised the company’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody’s report cites the Company’s strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics
Source: www.tevapharm.comCategories: General Medicine NewsTweet
-
Mashup Score: 2Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States - 2 month(s) ago
Press to close the select your country window or navigate to it’s content. EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive EPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris ® (eculizumab), making it one of the
Source: www.tevapharm.comCategories: General Medicine NewsTweet-
#NEWS: Teva and @SamsungBioepis announce launch of #raredisease #biosimilar in the U.S. Learn more: https://t.co/5mgY3TkiKJ $Teva https://t.co/QSXN8LB0FE
-
-
Mashup Score: 3Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention - 2 month(s) ago
Press to close the select your country window or navigate to it’s content. If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatments AJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options 1 These
Source: www.tevapharm.comCategories: General Medicine NewsTweet-
We are happy to share more on our continued commitment to support the care of #migraine patients. Read more here: https://t.co/fmzyAPr5Sz #TevaUSA https://t.co/HUfF6gpTjg
-
-
Mashup Score: 16Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease - 6 month(s) ago
Teva hosting investor call today at 8:00 a.m. ET (U.S.) Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: Teva and @Sanofi announce positive topline results for our anti-TL1A program for patients with #IBD. Read more here: https://t.co/dqvjiFygIS $Teva https://t.co/RJwVLFBca5
-
-
Mashup Score: 13Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States - 12 month(s) ago
Generic Victoza ® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch adds to Teva’s continued commitment to its complex generic medicine portfolio. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. PARSIPPANY,
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS Teva launches the first generic GLP-1 in the U.S., indicated to treat patients with #type2diabetes mellitus. This provides an important & in demand treatment option for patients, reinforcing Teva as a generics powerhouse. https://t.co/dBZEXHN7qs #TD2 #TevaUSA https://t.co/DLqnqVCuxR
-
-
Mashup Score: 5
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 (VMAT2) inhibitor for effective and tolerable tardive dyskinesia (TD) and Huntington’s disease (HD) chorea control 1 Patients with TD taking AUSTEDO XR can expect symptom improvement as early as two weeks while patients with HD chorea may experience a significant reduction in Total Maximal Chorea (TMC) score, with
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The US FDA has approved a new treatment associated with #tardivedyskinesia (TD) and #Huntingtonsdisease (HD) chorea for adults. Read more: https://t.co/6YpyQL93un #TevaUSA https://t.co/CqdHx8TLmD
-
-
Mashup Score: 9Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) - 1 year(s) ago
SELARSDI is a pproved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara SELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#News: A #biosimilar was approved by the FDA today for #psoriaticarthritis and #plaquepsoriasis. We'reproud to continue providing access to treatments for patients living with inflammatory conditions in partnership with @alvotechpr. https://t.co/MqcfrXMLHE https://t.co/Z8M43b55Hc
-
-
Mashup Score: 7Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting - 1 year(s) ago
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-’574) 1 Anti-TL1A (TEV-’574) was shown to be safe and well-tolerated, with a low incidence of antidrug antibodies 2 Data support the ongoing Phase 2b clinical investigation of anti-TL1A (TEV-’574) in inflammatory bowel disease 3 TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: We’re sharing new data about our innovative antibody candidate for #IBD at the European Crohn’s and Colitis Organisation (ECCO) Annual Congress. Read more about this new data here: https://t.co/NosOV8S3ib #TevaUSA #ECCO24 #CrohnsDisease #UlcerativeColitis https://t.co/ZgTRABabJd
-
-
Mashup Score: 3Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S. - 2 year(s) ago
Forteo® (teriparatide injection) is indicated to treat osteoporosis among certain women and men. This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering. The approval and subsequent launch will enhance access to a critical treatment option for patients while serving to de monstrate Teva’s strategic goal of sustaining a generic powerhouse. PARSIPPANY, N.J. & TEL AVIV, Israel–(BUSINESS WIRE)– Teva Pharmaceuticals Inc., a U.S. affiliate of Teva
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
Check out the latest generics news from Teva: https://t.co/gLGvo4JL0j $TEVA https://t.co/96V3MmjqmO
-
-
Mashup Score: 06 Ways to Cope Physically and Mentally when Self-Isolating - 5 year(s) ago
Barbara Stensland explains how life with MS has prepared her for the physical and mental challenges that come with self-isolation.
Source: www.tevapharm.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Tues. Apocalyptic chaos & looming COVID. Yet, life can’t be ignored. Rx, 1. Consistent routines. 2. Write down 3 priorities. Next steps? 3. Finish what we started. 4. Limit media access. 5. First things 1st or trivia consumes us. #resilience https://t.co/3PaIRETDiE https://t.co/d07jeOPMNp
-
Today @moodysratings has raised Teva’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Read the PR: https://t.co/FenZEACb6q $Teva